Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2007-1-26
pubmed:abstractText
Cizolirtine is a novel non-opioid drug which demonstrated antinociceptive activity in numerous pain models in rodents. Yet, its mechanism of action remains unknown. Several lines of evidence support the idea that adenosine (ADO) and serotonin (5-HT) modulate nociceptive signaling. Our study aimed at investigating whether these neuroactive molecules could be implicated in the mechanism of action of cizolirtine. Cizolirtine-induced antihyperalgesia was compared before and after pretreatment with ADO A(1)-A(2A) and 5-HT(1B/1D) receptor ligands in rats rendered diabetic by streptozotocin pretreatment and suffering from neuropathic pain. Cizolirtine alone (30-80 mg/kg, i.p.) significantly increased mechanical nociceptive thresholds. Acute pretreatment with the A(1)-A(2A) receptor antagonist caffeine (5 mg/kg, i.p.) or the 5-HT(1B/1D) receptor antagonist GR-127,935 (3 mg/kg, i.p.) significantly reduced the antihyperalgesic effects of cizolirtine. Conversely, cizolirtine-induced antihyperalgesia was promoted by pretreatment with either the selective A(1) receptor agonist CPA (0.3 mg/kg, i.p.) or the selective 5-HT(1B) receptor agonist CP-94,253 (3mg/kg, i.p.), and this potentiation was totally prevented by acute pretreatment with respective antagonists. Interestingly, A(1) receptor blockade by DPCPX inhibited the promoting effect of CP-94,253 on cizolirtine-induced antihyperalgesia, suggesting that the adenosine A(1)-mediated step takes place downstream the serotonin 5-HT(1B)-mediated step in the neurobiological mechanisms underlying cizolirtine action.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0028-3908
pubmed:author
pubmed:issnType
Print
pubmed:volume
52
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
487-96
pubmed:meshHeading
pubmed-meshheading:17027046-Adenosine, pubmed-meshheading:17027046-Analgesics, pubmed-meshheading:17027046-Animals, pubmed-meshheading:17027046-Area Under Curve, pubmed-meshheading:17027046-Caffeine, pubmed-meshheading:17027046-Diabetes Mellitus, Experimental, pubmed-meshheading:17027046-Diabetic Nephropathies, pubmed-meshheading:17027046-Disease Models, Animal, pubmed-meshheading:17027046-Dose-Response Relationship, Drug, pubmed-meshheading:17027046-Drug Interactions, pubmed-meshheading:17027046-Hyperalgesia, pubmed-meshheading:17027046-Male, pubmed-meshheading:17027046-Oxadiazoles, pubmed-meshheading:17027046-Pain Measurement, pubmed-meshheading:17027046-Pain Threshold, pubmed-meshheading:17027046-Piperazines, pubmed-meshheading:17027046-Psychomotor Performance, pubmed-meshheading:17027046-Pyrazoles, pubmed-meshheading:17027046-Rats, pubmed-meshheading:17027046-Rats, Sprague-Dawley, pubmed-meshheading:17027046-Serotonin, pubmed-meshheading:17027046-Serotonin Antagonists, pubmed-meshheading:17027046-Vocalization, Animal
pubmed:year
2007
pubmed:articleTitle
Evidence for adenosine- and serotonin-mediated antihyperalgesic effects of cizolirtine in rats suffering from diabetic neuropathy.
pubmed:affiliation
INSERM, U677, and Université Pierre et Marie Curie-Paris6, Faculté de Médecine Pierre et Marie Curie, Site Pitié-Salpétrière, UMR S677, 91 Boulevard de l'Hôpital, Paris F-75013, France.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't